COSMO Pharmaceuticals N.V. (CH:COPN)
:COPN
Want to see CH:COPN full AI Analyst Report?
COPN Stock Chart & Stats
CHF97.80
-CHF3.50(-5.38%)
At close: 4:00 PM EST
CHF97.80
-CHF3.50(-5.38%)
Day’s Range― - ―
52-Week RangeCHF53.40 - CHF129.40
Previous CloseN/A
Volume25.75K
Average Volume (3M)19.52K
Market Cap
CHF1.22B
Enterprise ValueCHF1.33B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Jul 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF143.33Price Target Upside46.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.1
Revenue Forecast (FY)CHF106.30M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low debt and substantial equity provide durable financial flexibility. That conservatism gives the company runway to fund R&D, support product commercialization or absorb temporary cash shortfalls without forcing dilutive financing, strengthening long-term operational resilience.
Specialized Gastroenterology FocusA narrow clinical focus on gastroenterology/endoscopy creates durable competitive advantages: deep clinical expertise, targeted sales channels, and higher switching costs with specialist customers. This positioning supports repeatable product adoption and licensing appeal to partners.
Demonstrated High-margin PotentialThe company has shown it can deliver very high margins in favorable years, indicating scalable commercial economics and valuable proprietary products. That structural potential supports long-term profitability if product mix, commercialization, or partner licenses re-attain prior levels.
Bears Say
Sharp Revenue Decline In 2025A large, rapid drop in revenue undermines durable revenue visibility and makes multi-quarter planning difficult. Structural declines of this magnitude can erode commercial momentum, strain partner relationships, and require sustained operational adjustments to restore prior scale.
Weak Cash Generation In Latest YearNegative operating and free cash flow erode the company's ability to self-fund R&D, regulatory work, and commercialization. Persistent cash burn would force reliance on the balance sheet or external financing, reducing strategic optionality and increasing execution risk over months.
Revenue Model Driven By Lumpy Licensing/milestonesDependence on upfront/milestone licensing creates inherently lumpy, timing-sensitive revenue. That structural feature drives earnings volatility, complicates forecasting and investor visibility, and can produce abrupt swings in reported profitability and cash flow over multi-quarter horizons.
COSMO Pharmaceuticals N.V. News
COPN FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was CHF53.40 and its highest was CHF129.40 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.22B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 20, 2026 which is in 45 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.091 earnings per share for the quarter, missing the consensus estimate of CHF0.183 by -CHF0.274.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.918 which represents an annual dividend yield of 1.82%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.091 in its last earnings report, missing expectations of CHF0.183. Following the earnings report the stock price went down -10.522%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CH:COPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
COPN Stock 12 Month Forecast
Average Price Target
CHF143.33
▲(46.56% Upside)
Technical Analysis
Options Prices
Currently, No data available
---